Longer tamoxifen use helps stave off breast cancer; Caraco, DUSA win antitrust nod for buyout;

@FiercePharma: Teva investors want new CEO Jeremy Levin to say he has their back in next week's analyst presentation. News | Follow @FiercePharma

> Ten years of breast cancer treatment with tamoxifen beat the standard 5 years at stopping recurrence and cutting the death rate, without a big increase in the risk of endometrial cancer. Report (sub. req.)

> Caraco Pharmaceutical, the U.S. unit of India's Sun Pharmaceutical Industries, won early approval for its buyout of DUSA Pharmaceuticals. Report

> India is looking at exporting more drugs to Iran to help alleviate shortages there. Report

> Pfizer ($PFE) agreed to allow its Elelyso partner Protalix BioTherapeutics to continue managing ongoing clinical trials of the drug, while Pfizer will handle new trials. Report

> Researchers say coatings on aspirin tablets may be responsible for some patients' less-than-adequate response to daily low-dose therapy. Report

Medical Device News

 @FierceMedDev: Industry groups urge Congress to delay device tax. Story | Follow @FierceMedDev

@MarkHFierce: Research at Columbia proposes the use of a prenatal genetic test as standard of care--it's much more comprehensive. Item | Follow @MarkHFierce

 @DamianFierce: In case you missed it, we rounded up some industry reaction to the final medical device tax regs. Story | Follow @DamianFierce

> Many hospitals don't protect devices from hackers, study says. Story

> Study: ICDs mar kids' quality of life. Report

Biotech News

 @FierceBiotech: Eli Lilly touts antibody that reverses symptom of Alzheimer's. News | Follow @FierceBiotech

@JohnCFierce: Biotech upstart Moderna nails down $40M for bold RNA idea. Article | Follow @JohnCFierce

 @RyanMFierce: FDA is on track to increase new drug approvals again. But is it enough? Story (sub. req.) | Follow @RyanMFierce

> FDA matches most new drug approvals in years in 2012; Is it enough? Report

> Against tough odds, Lundbeck touts high-stakes R&D end game. Story

> Biotech upstart Moderna nails down $40M for bold RNA idea. Article

Vaccines News

 @AlisonBFierce: FhCMB lands up to $9.9M from NIH for anthrax vaccine research. More | Follow @AlisonBFierce

> Flu season arrives a month early. Item

> DARPA tackles the DNA vaccine. Article

> Protein Sciences expands flu vaccine operations to Pfizer site. More

> Altravax lands $3.45M from NIH for HIV vaccine research. News

> Sanofi Pasteur nabs Menactra expansion in Canada. Story

Pharma Manufacturing News

 @EricPFierce: Happy Holidays from FDA. It extends to Dec. 18 the deadline to register API and generic drug manufacturing plants. More | Follow @EricPFierce

> Sun setting on Sunovion Canadian API plant. Article

> Cargo theft law puts target on organized crime. News

> Lilly taps Strides, Agila for cancer med manufacturing. Story

> FDA registration deadline looms for generic drugmakers. Report

And Finally... Novo Nordisk ($NVO) has launched the world's first all-diabetic cycling team, which comprises 17 riders from around the world. Report


Suggested Articles

Stephen Hahn, an oncologist who served as the chief medical officer for the MD Anderson Cancer Center, has secured Senate confirmation as FDA head.

As BMS searches for bright spots in its Opdivo-chemo combo fail from June, it’s zeroing in on squamous lung cancer patients who seemed to benefit.

The FDA's ad watchdog served its most serious violation to Alkermes Wednesday—and it took the unusual step of announcing that violation to the world.